Molecules 2013-01-01

The synthesis and evaluation of novel hydroxyl substituted chalcone analogs with in vitro anti-free radicals pharmacological activity and in vivo anti-oxidation activity in a free radical-injury Alzheimer's model.

Ying Pan, Yicun Chen, Qingnan Li, Xiaoyu Yu, Jinzhi Wang, Jinhong Zheng

Index: Molecules 18(2) , 1693-703, (2013)

Full Text: HTML

Abstract

Alzheimer's disease (AD) pathogenesis involves an imbalance between free radical formation and destruction. In order to obtain a novel preclinical anti-AD drug candidate, we synthesized a series of novel hydroxyl chalcone analogs which possessed anti-free radical activity, and screened their effects on scavenging 2,2-diphenyl-1-picrylhydrazyl (DPPH) and OH free radicals in vitro. Compound C7, 4,2'-dihydroxy-3,5-dimethoxychalcone was found to have potent activity in these anti-free radical activity tests. Further research revealed that C7 could elevate glutathione peroxidase (GSH-PX) and super oxide dismutase (SOD) levels and lower malonaldehyde (MDA) level in vivo in the Alzheimer's model. The indication of C7's effect on AD needs further study.


Related Compounds

Related Articles:

Antimycobacterial and anti-inflammatory activities of substituted chalcones focusing on an anti-tuberculosis dual treatment approach.

2015-01-01

[Molecules 20 , 8072-93, (2015)]

Comparative analysis of the main bioactive components of San-ao decoction and its series of formulations.

2012-01-01

[Molecules 17(11) , 12925-37, (2012)]

Development of a stability-indicating LC method for determination of a synthetic chalcone derivative in a nanoemulsion dosage form and identification of the main photodegradation product by LC-MS.

2012-11-01

[J. Pharm. Biomed. Anal. 70 , 652-6, (2012)]

Bifendate-chalcone hybrids: a new class of potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.

2014-12-12

[Biochem. Biophys. Res. Commun. 455(3-4) , 318-22, (2014)]

Inhibitory effects of hydroxysafflor yellow A on the formation of advanced glycation end products in vitro.

2012-01-01

[Biol. Pharm. Bull. 35(11) , 2050-3, (2012)]

More Articles...